Arrhythmias are a common state of abnormal heart rhythms. Ace Therapeutics aims to provide clients with integrated services for basic research and drug development for arrhythmias to further investigate the pathogenesis of different types of arrhythmias as well as their therapeutic approaches.
Arrhythmias are heart rhythm disorders caused by abnormal sinus node excitation or excitation arising outside the sinus node, slow or blocked conduction of excitation, or conduction through abnormal channels. The prognosis of an arrhythmia is related to its etiology, its triggers, its evolution and whether it leads to a serious hemodynamic disorder, which may occur suddenly and lead to sudden death, or it may continue to involve the heart and lead to heart failure. Elucidating the pathogenesis of various types of arrhythmias will undoubtedly greatly facilitate the development of drugs for the therapy of arrhythmias.
Fig. 1 Major genes associated with congenital arrhythmias. (Glazer A, 2022)
When it comes to anti-arrhythmic drug development, traditional drug targets mainly focus on sodium channels, calcium channels, and adrenergic receptors. In recent years, some novel therapeutic approaches have also been gradually applied to the field of antiarrhythmic drug development.
| Drug Name | Drug Target | Original Organization | Drug Phase |
|---|---|---|---|
| Sodium Zirconium Cyclosilicate | Potassium | AstraZeneca Pharmaceuticals Co., Ltd. | Approved |
| Dronedarone Hydrochloride | ADRA1 / Cav1.2 / Potassium channel / β1-adrenergic receptor | Sanofi | Approved |
| Ranolazine | Nav1.5 | Gilead Sciences, Inc. | Approved |
| Etripamil | L-type calcium channel | Milestone Pharmaceuticals, Inc. | NDA |
| Azimilide Hydrochloride | Potassium channel | Allergan Ltd. (Ireland) | Phase 3 |
| NAN-101 | DUSP1 | NanoCor Therapeutics, Inc. and Asklepios BioPharmaceutical, Inc. | Phase 2 |
| RP-A601 | plakophilin-2 | Rocket Pharmaceuticals, Inc. | Phase 1 |
Ace Therapeutics is committed to supporting basic research and development of novel therapeutic approaches for arrhythmias by providing outsourced research services for disease model development and related research technology platforms.
Research Models
Basic Research
Drug Development
A good arrhythmia research model can provide a good research platform for the pathogenesis of arrhythmia as well as for evaluating the effects of drug therapy. We are able to provide our customers with various types of arrhythmia animal models, genetically engineered mouse models and cardiomyocyte cell lines to support their research in the field of cardiac arrhythmia.
Custom Animal Model Development Services
Commonly used animal models for arrhythmia research include mice, rats, guinea pigs, rabbits and dogs. We can provide customized arrhythmia animal model construction services to help our clients better conduct arrhythmia experimental research.
Transgenic Animal Model Development Services
We can provide customized services for developing transgenic or knockout animal models, including but not limited to the following genes:
Genetically Engineered Mouse Models
We can provide the following high quality genetically engineered mice for arrhythmia research.
Cardiomyocyte Cell Lines
For in vitro studies, we can provide our clients with a wide range of cardiomyocyte cell lines.
For arrhythmia research, we have a specialized platform for in vitro hERG experiments as well as imaging analysis technology, which can help researchers evaluate the potential arrhythmogenic effects of drugs.
In Vitro hERG Assays
Inducing arrhythmia is one of the common toxic side effects of drugs, and testing the inhibitory effect of compounds on hERG ion channels is now one of the key components of preclinical evaluation of drugs. We can provide the following technical methods to test the inhibitory effect of drugs on hERG ion channels:
In Vivo Electrocardiography (ECG) Services
ECG is the most common and intuitive method for detecting arrhythmias, both in clinical diagnosis and in experimental research. We can provide in vivo ECG diagnostic and monitoring services for animal experiments.
Based on our specialized technology platform, we can provide our clients with arrhythmia drug development services.
R&D Services by Drug Type
R&D Services by Target
Ace Therapeutics has extensive experience in the field of cardiac arrhythmia research and can provide clients with specialized basic research services as well as the construction of animal disease models to help advance the development of novel therapies for the therapy of cardiac arrhythmias. If you are interested in our research services for arrhythmia research, please don't hesitate to contact us.
Ace Therapeutics offers comprehensive solutions and R&D services to researchers worldwide to advance the field of cardiovascular diseases.
We do not provide medical care for patients.
Copyright © Ace Therapeutics. All rights reserved.